The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
There is growing interest in identifying predictive biomarkers for inhibitors of programmed cell death protein 1 receptor (PD‐1), programmed death ligand 1 (PD‐L1), and cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4). Given the links between the stool microbiota, anticancer immunosurveillance, and general health, the composition of the gut microbiome has recently undergone investigation as a biomarker for immunotherapy. In this review, we highlight published results from preclinical and clinical studies to date supporting a relationship between the gut microbiome and antitumor efficacy of immune checkpoint inhibitors. Despite the promising and hypothesis‐generating findings that have been produced in this arena to date, there remain some inconsistencies amongst present data that may need to be resolved to contribute to further development. Among these, a better understanding of the immunomodulatory function of the microbiome, standardization in sampling, sequencing techniques, and data analysis, and ensuring uniformity across various aspects of study design are warranted in conducting future prospective studies seeking to validate the gut microbiome as a potential biomarker of response to checkpoint blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 6×
“in mice cotreated with antiPD-L1 therapy was shown to increase antigen-specific CD8+ TILs and MHC Class II DCs, while abundance of Clostridiales order, Ruminococcaceae family, and Faecalibacterium genus was associated with increased CD8+ TILs and peripheral blood CD4+/CD8+ T-cells in human responders to PD-1 blockade…”
BackgroundResultInfluentialCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 3×
“in mice cotreated with antiPD-L1 therapy was shown to increase antigen-specific CD8+ TILs and MHC Class II DCs, while abundance of Clostridiales order, Ruminococcaceae family, and Faecalibacterium genus was associated with increased CD8+ TILs and peripheral blood CD4+/CD8+ T-cells in human responders to PD-1 blockade…”
BackgroundAnalysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 1×
“Tumors harboring mutations in DNA mismatch repair genes resulting in microsatellite instability (MSI) or DNA polymerases (POLE) represent other phenotypes with high mutational load that can predict response to checkpoint blockade [4].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 5×
“Anti‐CTLA‐4 antibodies In a subsequent study, tumor-bearing mice housed in germ-free conditions or treated with antibiotics experienced comprised antitumor effects with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) therapy that were associated with significantly decreased effector CD4+ T-cells and tumor-in…”
BackgroundInfluentialThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392 · cited 1×
“Additionally, greater understanding of underlying mechanisms may be afforded in research on the contribution of the microbiome to therapy-induced anticancer immune responses across other treatment modalities beyond checkpoint inhibition such as chemotherapy, radiation therapy, hematopoietic stem cell transplantation,…”
BackgroundHow informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334 · cited 3×
“The anatomical structures and intestinal wall linings have been shown to significantly differ across human and mouse gastrointestinal tracts [39].”
BackgroundInfluentialChaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Cited by
The Controversial Role of Human Gut Lachnospiraceae
Vacca, M., Celano, G., Calabrese, F. M., Portincasa, P., Gobbetti, M., & De Angelis, M. (2020) · Microorganisms · doi:10.3390/microorganisms8040573 · Cited by 1,688
Sex disparities matter in cancer development and therapy
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B., & Haupt, Y. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00348-y · Cited by 331
Choi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 298
Hussain, N., Naeem, M., & Pinato, D. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1769398 · Cited by 69
Biomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Metadata
- Authors
- Gong, J., Chehrazi‐Raffle, A., Placencio‐Hickok, V., Guan, M., Hendifar, A., & Salgia, R.
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2019-03-18
- Volume
- 8
- Issue
- 1
- Pages
- 9-9
- ISSN
- 2001-1326 (ISSN-L)
- OpenAlex
- W2938994710
- Cited by
- 113
- References
- 20
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. https://app.cochat.ai/papers/10.1186/s40169-019-0225-x
- The paper
- Gong, J., Chehrazi‐Raffle, A., Placencio‐Hickok, V., Guan, M., Hendifar, A., & Salgia, R. (2019). The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clinical and Translational Medicine. https://doi.org/10.1186/s40169-019-0225-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.